Vitamin D identified as the dietary or sunlight factor involved in rickets problems

An inherited form of rickets identified which is not susceptible to Vitamin D supplementation in diet

Hypophosphatemia identified as the important X-Linked component in Vitamin D Resistant Rickets in a study based on families in the Carolinas, USA.

High dose Vitamin D used as early therapy

Phosphate supplements tried in an attempt to normalize blood phosphate

Active D3 hormone used in some trials, with unforeseen and sometimes disastrous side-effects

Phosphate supplementation and calcitriol co-therapy used to enhance blood phosphate

Mice with the hyp mutation identified which appear to have similar symptoms to those in human XLH

Professional querying of efficacy of therapy in XLH

Consensus holds that therapy with phosphate and calcitriol has some benefits for some patients, particularly in straightening of lower limbs, although final height may not be enhanced, and some patients may not respond

Identification of the genetic defect responsible for XLH (PEX, later termed PHEX) by the Hyp consortium

Vitamin D 24,25 D3 identified as potentially useful therapy

Vitamin D Metabolism and Rickets web pages created. Colin Steeksma and Larry Winger collaborate to form an internet-based support group.

St. John's University, New York agrees to host F-HYPDRR mailing list

Theory advanced regarding PHEX chemical biofeedback and a substance called phosphatonin

F-HYPDRR mailing list reaches 100 members (2 years after list inception)

French study concludes disorder severity does not correlate with specific XLH mutation.

PHEX mutational database announced

Bone marrow transplantation success announced in hyp mice

Announcement of MEPE compound (identified in rare bone tumors) as prime phosphatonin candidate

F-HYPDRR mailing list reaches 200th member (not quite 4 years after inception)

The gene which is affected in Autosomal Dominant Hypophosphatemic Rickets is identified (FGF23)

PHEX is expressed in an active soluble form

A variety of possible contenders for the phosphatonin hormone are considered

Yves Sabbagh, of Montreal, research member of F-HYPDRR, receives the Young Investigator of the Year award from the American Society for Bone & Mineral Research